Newly identified protein could be used to fight HIV
A new protein has been identified that has broad virus-fighting properties which potentially could be used as a weapon against deadly human pathogenic viruses like HIV.
|Last Updated: Feb 12, 2013, 03:22 PM IST|Source: Bureau
Washington: A new protein has been identified that has broad virus-fighting properties which potentially could be used as a weapon against deadly human pathogenic viruses like HIV, Ebola, Rift Valley Fever, Nipah and others designated "priority pathogens."
The team of UCLA-led researchers described the antiviral property of the protein, cholesterol-25-hydroxylase (CH25H), an enzyme that converts the cholesterol to an oxysterol called 25-hydroxycholesterol (25HC), which can permeate a cell`s wall and block a virus from getting in.
Working with Jerome Zack, a professor of microbiology, immunology and molecular genetics and an associate director of the UCLA AIDS Institute, the researchers initially found that 25HC dramatically inhibited HIV in cell cultures.
Next, they administered 25HC in mice implanted with human tissues and found that it significantly reduced their HIV load within seven days. The 25HC also reversed the T-cell depletion caused by HIV.
The researchers found that by contrast, mice that had the CH25H gene knocked out were more susceptible to a mouse gammaherpes virus.
In collaboration with Dr. Benhur Lee , a professor of pathology and laboratory medicine and a member of the UCLA AIDS Institute, the scientists discovered that 25HC inhibited HIV entry into the cell.
Furthermore, in cell cultures, it was found to inhibit the growth of other deadly viruses, like Ebola, Nipah and the Rift Valley Fever virus.
Intriguingly, CH25H expression in cells requires interferon, which for more than 60 years has been known to be a critical part of the body`s natural defense mechanism against viruses, the protein itself does not have any antiviral properties. Rather, it triggers the expression of many antiviral genes.
Lead author Su-Yang Liu, a student in the department of microbiology, immunology and molecular genetics at the David Geffen School of Medicine at UCLA noted some weaknesses in the research. For instance, 25HC is difficult to deliver in large doses, and its antiviral effect against Ebola, Nipah and other highly pathogenic viruses have yet to be tested in vivo. Also, the researchers still need to compare 25HC`s antiviral effect against other HIV antivirals.
The study has been published in the January issue of the journal Immunity.
ANI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.